Overview

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Status:
Not yet recruiting

Trial end date:
2027-12-30

Target enrollment:

Participant gender:

Summary

This is a randomized, controlled, double-blind, single-center Phase III clinical study in patients with EGFR/ALK mutation negative stage II-IIIB (N2) non-small cell lung cancer (NSCLC) after complete tumor resection. To evaluate the effectiveness and safety of toripalimab compared with placebo combined with platinum-containing dual-drug chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Shanghai Pulmonary Hospital, Shanghai, China

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Docetaxel
Gemcitabine
Paclitaxel
Pemetrexed
Vinorelbine